Literature DB >> 22389255

The HMGA1 protoncogene frequently deregulated in cancer is a transcriptional target of E2F1.

Isabella Massimi1, Francesca Guerrieri, Marialaura Petroni, Veronica Veschi, Silvia Truffa, Isabella Screpanti, Luigi Frati, Massimo Levrero, Alberto Gulino, Giuseppe Giannini.   

Abstract

Reactivation of the HMGA1 protoncogene is very frequent in human cancer, but still very little is known on the molecular mechanisms leading to this event. Prompted by the finding of putative E2F binding sites in the human HMGA1 promoter and by the frequent deregulation of the RB/E2F1 pathway in human carcinogenesis, we investigated whether E2F1 might contribute to the regulation of HMGA1 gene expression. Here we report that E2F1 induces HMGA1 by interacting with a 193 bp region of the HMGA1 promoter containing an E2F binding site surrounded by three putative Sp1 binding sites. Both gain and loss of function experiments indicate that Sp1 functionally interacts with E2F1 to promote HMGA1 expression. However, while Sp1 constitutively binds HMGA1 promoter, it is the balance between different E2F family members that tunes the levels of HMGA1 expression between quiescence and proliferation. Finally, we found increased HMGA1 expression in pituitary and thyroid tumors developed in Rb(+/-) mice, supporting the hypothesis that E2F1 is a novel important regulator of HMGA1 expression and that deregulation of the RB/E2F1 path might significantly contribute to HMGA1 deregulation in cancer.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22389255     DOI: 10.1002/mc.21887

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  14 in total

1.  PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.

Authors:  V Colicchia; M Petroni; G Guarguaglini; F Sardina; M Sahún-Roncero; M Carbonari; B Ricci; C Heil; C Capalbo; F Belardinilli; A Coppa; G Peruzzi; I Screpanti; P Lavia; A Gulino; G Giannini
Journal:  Oncogene       Date:  2017-04-10       Impact factor: 9.867

Review 2.  High Mobility Group A1 (HMGA1): Structure, Biological Function, and Therapeutic Potential.

Authors:  Lu Wang; Ji Zhang; Min Xia; Chang Liu; Xuyu Zu; Jing Zhong
Journal:  Int J Biol Sci       Date:  2022-07-04       Impact factor: 10.750

3.  TGF-β1 induces HMGA1 expression in human breast cancer cells: implications of the involvement of HMGA1 in TGF-β signaling.

Authors:  Xuyu Zu; Jing Zhong; Jingjing Tan; Li Tan; Dong Yang; Qinghai Zhang; Wenjun Ding; Wen Liu; Gebo Wen; Jianghua Liu; Renxian Cao; Yuyang Jiang
Journal:  Int J Mol Med       Date:  2015-01-05       Impact factor: 4.101

Review 4.  HMGA proteins as modulators of chromatin structure during transcriptional activation.

Authors:  Nihan Ozturk; Indrabahadur Singh; Aditi Mehta; Thomas Braun; Guillermo Barreto
Journal:  Front Cell Dev Biol       Date:  2014-03-06

5.  Most of the tight positional conservation of transcription factor binding sites near the transcription start site reflects their co-localization within regulatory modules.

Authors:  Natalia Acevedo-Luna; Leonardo Mariño-Ramírez; Armand Halbert; Ulla Hansen; David Landsman; John L Spouge
Journal:  BMC Bioinformatics       Date:  2016-11-21       Impact factor: 3.169

Review 6.  Advancements in the study of miRNA regulation during the cell cycle in human pituitary adenomas.

Authors:  Ting Zhang; Zijiang Yang; Heng Gao
Journal:  J Neurooncol       Date:  2017-06-02       Impact factor: 4.130

7.  High-SETD8 inactivates p53 in neuroblastoma.

Authors:  Veronica Veschi; Carol J Thiele
Journal:  Oncoscience       Date:  2017-04-14

8.  Increased E2F1 mRNA and miR-17-5p Expression Is Correlated to Invasiveness and Proliferation of Pituitary Neuroendocrine Tumours.

Authors:  Araceli García-Martínez; Beatriz López-Muñoz; Carmen Fajardo; Rosa Cámara; Cristina Lamas; Sandra Silva-Ortega; Ignacio Aranda; Antonio Picó
Journal:  Diagnostics (Basel)       Date:  2020-04-16

9.  HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance.

Authors:  Rossella Loria; Valentina Laquintana; Giulia Bon; Daniela Trisciuoglio; Roberta Frapolli; Renato Covello; Carla Azzurra Amoreo; Virginia Ferraresi; Carmine Zoccali; Mariangela Novello; Donatella Del Bufalo; Michele Milella; Roberto Biagini; Maurizio D'Incalci; Rita Falcioni
Journal:  Oncogene       Date:  2018-07-06       Impact factor: 9.867

10.  MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.

Authors:  Marialaura Petroni; Francesca Sardina; Paola Infante; Armando Bartolazzi; Erica Locatelli; Francesca Fabretti; Stefano Di Giulio; Carlo Capalbo; Beatrice Cardinali; Anna Coppa; Alessandra Tessitore; Valeria Colicchia; Maria Sahùn Roncero; Francesca Belardinilli; Lucia Di Marcotullio; Silvia Soddu; Mauro Comes Franchini; Elena Petricci; Alberto Gulino; Giuseppe Giannini
Journal:  Cell Death Dis       Date:  2018-08-30       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.